Key result
Darbepoetin-alpha administered prior to ischemia improved left ventricular shortening and ejection fractions compared to control (P < 0.05) in a rat model of myocardial ischemia and reperfusion.
Why the study?
Does darbepoetin-alpha improve left ventricular function and reduce infarct size in a rat myocardial ischemia and reperfusion model?
Does darbepoetin-alpha improve left ventricular function and reduce infarct size in a rat myocardial ischemia and reperfusion model?
p-value: p=< 0.05
Darbepoetin-alpha provides short- and long-term cardioprotection in a rat ischemia-reperfusion model by reducing apoptosis through the Akt/Bcl-2/GSK-3beta pathway.
May support preclinical cardioprotection research; leaves open translation to human ischemia-reperfusion injury.
The purpose of this study was to assess the short- and long-term cardioprotective effects of darbepoetin-alpha (DA) in a rat myocardial ischemia and reperfusion model and to investigate the signaling pathway through which DA limits cardiomyocytes apoptosis. Rats were subjected to 40 minutes of coronary artery ligation followed by 72 hours or 4 weeks reperfusion and received either DA (3 or 30 microg/kg, DA3 and D30 groups) or vehicle (control) prior to ischemia. In the DA groups reperfused for 72 hours, left ventricular shortening fraction and left ventricular ejection fraction were higher than that in the control rats (P < 0.05), in agreement with a smaller left ventricular (LV) infarct size. DA treatment activated the JAK2/Akt signaling pathway, lowered cleaved caspase-3, and increased both phosphorylated-Bad and phosphorylated-GSK-3beta proteins. This was consistent with the decrease of reactive oxygen species production and the lowered binding of Bad to Bcl-xL and Bcl-2 in a DA30 group of rats. Similarly, in the DA-4-week group, LV function was greater compared to the control. Histology alterations implicated lower LV cardiac fibrosis and greater capillary density; furthermore, both Bcl-xL and Bcl-2 were upregulated. In conclusion, DA afforded short- and long-term cardioprotective effects. Antiapoptotic effects, through the activation of Akt that regulates the Bcl-2 family proteins and activates GSK-3beta, are central in the DA cardioprotective mechanism.
No takes yet. Share an insight, caveat, or question.
Schlecht-Bauer et al. (2009) studied Myocardial ischemia and reperfusion. Darbepoetin-alpha vs. Vehicle was evaluated on Left ventricular shortening fraction and left ventricular ejection fraction (p=< 0.05). Darbepoetin-alpha administered prior to ischemia improved left ventricular shortening and ejection fractions compared to control (P < 0.05) in a rat model of myocardial ischemia and reperfusion.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: